Jul 5, 2021

Health Recovery Solutions: The new standard of care

MercyOne
Health Recovery Solutions
3 min
With a strategic focus around remote patient monitoring and telehealth services, here’s a look at how HRS is at the forefront of transformative care.

It is safe to say that COVID-19 has impacted the healthcare sector in more ways than one. From switching entire systems to virtual overnight, ramping up around the clock service and revamping the entire patient care model, a lot is to be said about the digital transformation of the sector at large. Technology partners are working tirelessly at the frontline in efforts to boost patient care and safety, and one such organisation is Health Recovery Solutions.

Founded in 2012 by three college roommates in a one-bedroom, New York City apartment, HRS has come a long way from its humble beginnings. Today, HRS partners with over 220 leading health systems, spanning 46 states, servicing nearly 225,000 patients, across 90 disease conditions. It is now a nationally recognized provider of telehealth and remote patient monitoring solutions. In order to best understand the advantage of having a remote monitoring solution in place, Sudeep Pisipaty, VP of Strategy and Value-Based Care explains "For many patients, including high-risk, chronic patients, they're often discharged without digital tools to aide them in their recovery process. It's these patients we see return back to the hospitals, and the same patients we have opportunity to engage, intervene, and empower in self-care management.” HRS’ focus is to empower patients with technology-based solutions to help them manage their diagnosis independently, but also help healthcare providers, like MercyOne, manage total cost of care over time.

Speaking about how HRS started collaborating with large-scale providers, Doug Lang, HRS’ VP of Client Growth says, “For the last 10 years we've been working with hundreds of providers across the entire landscape. We really got our start with home health agencies, because they were the path of least resistance and already had the infrastructure and workflows to monitor these patients.” Soon after, the team at HRS was fully involved with transforming RPM to larger regional medical establishments – from physician groups to health systems and payers.

Healthcare providers today are faced with a number of challenges when considering a shift to remote monitoring, a prominent one being the lack of appropriate infrastructure. HRS recognizes this challenge and aids providers in increasing workflow efficiency and capacity for care and maximising value in terms of what’s delivered to patients. Furthermore, COVID-19 has caused rural communities to become cut off due to travel restrictions, and health centres are experiencing an overall shortage of physicians and nurses due to employee burnout. A silver lining to the pandemic, however, is that the possibilities of telehealth have been brought into the spotlight. Remote connectivity solutions have now enabled patients to connect with their providers, families and caregivers without putting their lives at risk. 

HRS provides a number of ancillary Bluetooth peripherals such as pulse oximeters, heart and lung rhythm devices, scales, and BP monitors. These allow patients the freedom to virtually connect to their clinician and health centres without stepping foot outside their homes. HRS’ goal is to create a device-agnostic environment as the world continues to adopt a lower-touch model as the new standard of care. 

 

 

Share article

Aug 4, 2021

C. Light aim to detect Alzheimer's with AI and eye movements

alzheimers
AI
Technology
healthcare
3 min
C. Light aim to detect Alzheimer's with AI and eye movements
C. Light Technologies will use AI to study eye movements and monitor the progression of Alzheimer's

 C. Light Technologies, a neurotechnology and AI company based in Boston, has received funding for a pilot study that will assess changes in eye motion during the earliest stage of Alzheimer's, known as mild cognitive impairment. 

C. Light Technologies has partnered with the UCSF Memory and Aging Center for this research. As new therapeutics for Alzheimer’s are introduced to the clinic, this UCSF technology has the potential to provide clinicians a better method to measure disease progression, and ultimately therapeutic efficacy, using C. Light’s novel retinal motion technology.

Eye motion has been used for decades to triage brain health, which is why  doctors asks you to “follow my finger” when they want to assess whether you have concussion. In more than 30 years of research, studies have revealed that Alzheimer’s disease patients' eye movements are affected by the disease, though to date, these eye movements have only been measured on a larger scale.

C. Light’s research takes the eye movement tests to a microscopic level for earlier assessments. Clinicians can study and measure eye motion on a scale as small as 1/100th the size of a human hair, which can help them monitor a patient’s disease and treat it more effectively.

The tests are also easy to administer. Patients put their chin in a chinrest and  focus on a target for 10 seconds. The test does not require eye dilation, and patients are permitted to blink. A very low-level laser light is shown through the pupil and reflects off the patient’s retina, while a sensitive camera records the cellular-level motion in a high-resolution video. This eye motion is then  fed into C. Light’s advanced analytical platform.

“C. Light is creating an entirely new data stream about the status of brain health via the eye,” explains Dr. Christy K. Sheehy, co-founder of C. Light.  “Our growing databases and accompanying AI can change the way we monitor and treat neurological disease for future generations. Ultimately, we’re working to increase the longevity and quality of life for our loved ones." 

At the moment developing therapeutic treatments for the central nervous system is difficult, with success rates of only 8% to go from conception to market. One reason for this is the lack of tools to measure the progression of diseases that impact the nervous system. 

Additionally clinical trials can take a decade to come to fruition because the methods used to assess drug efficacy are inefficient. C. Light believe they can change this. 

“Before this year, it had been almost 20 years since an Alzheimer’s drug was brought to market" explains Sheehy. "Part of the reason for this very slow progress is that drug developers haven’t had viable biomarkers that they can use to effectively stratify patients and track disease on a fine scale. The ADDF’s investment will allow us to do that." 

C. Light has received the investment from the Alzheimer’s Drug Discovery Foundation (ADDF) through its Diagnostics Accelerator, a collaborative research initiative supported by Bill Gates, the Dolby family, and Jeff Bezos among other donors. 

C. Light recently completed its second and final seed round raising $500,000, including the ADDF investment, which brings their total seed funding to more than $3 million. Second round seed funders included: ADDF, the Wisconsin River Business Angels, Abraham Investments, LLC and others.
The ADDF’s Diagnostics Accelerator has made previous investments in more than two dozen world-class research programmes to explore blood, ocular, and genetic biomarkers, as well as technology-based biomarkers to identify the early, subtle changes that happen in people with Alzheimer’s. 

Share article